Literature DB >> 26112199

Cardiovascular Health of Patients With Cancer and Cancer Survivors: A Roadmap to the Next Level.

Ana Barac1, Gillian Murtagh2, Joseph R Carver3, Ming Hui Chen4, Andrew M Freeman5, Joerg Herrmann6, Cezar Iliescu7, Bonnie Ky8, Erica L Mayer9, Tochi M Okwuosa10, Juan Carlos Plana11, Thomas D Ryan12, Anne K Rzeszut13, Pamela S Douglas14.   

Abstract

Many existing and emerging cancer therapies have a significant effect on the cardiovascular health of patients with cancer and cancer survivors. This paper examines current aspects of interdisciplinary cardio-oncology clinical care delivery and education in the United States and outlines how these data provide a platform for future development of the field. We present the results of the nationwide survey on cardio-oncology services, practices, and opinions, conducted among chiefs of cardiology and program directors, which demonstrate ranges of clinical activities and identify significant interest for increased educational opportunities and expert training of cardiovascular physicians in this field. The survey respondents recognized clinical relevance but emphasized lack of national guidelines, lack of funds, and limited awareness and infrastructure as the main challenges for development and growth of cardio-oncology. We discuss potential solutions to unmet needs through interdisciplinary collaboration and the active roles of professional societies and other stakeholders.
Copyright © 2015 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  cancer survivorship; cardio-oncology; cardiovascular risk prevention; cardiovascular toxicity

Mesh:

Year:  2015        PMID: 26112199      PMCID: PMC4484773          DOI: 10.1016/j.jacc.2015.04.059

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  37 in total

1.  Onco-cardiology: the time has come.

Authors:  Edward T H Yeh
Journal:  Tex Heart Inst J       Date:  2011

2.  Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation.

Authors:  Daniela Cardinale; Alessandro Colombo; Rosalba Torrisi; Maria T Sandri; Maurizio Civelli; Michela Salvatici; Giuseppina Lamantia; Nicola Colombo; Sarah Cortinovis; Maria A Dessanai; Franco Nolè; Fabrizio Veglia; Carlo M Cipolla
Journal:  J Clin Oncol       Date:  2010-08-02       Impact factor: 44.544

3.  Left ventricular dysfunction in patients receiving cardiotoxic cancer therapies are clinicians responding optimally?

Authors:  Geoffrey J Yoon; Melinda L Telli; David P Kao; Kelly Y Matsuda; Robert W Carlson; Ronald M Witteles
Journal:  J Am Coll Cardiol       Date:  2010-11-09       Impact factor: 24.094

4.  Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab.

Authors:  Heloisa Sawaya; Igal A Sebag; Juan Carlos Plana; James L Januzzi; Bonnie Ky; Timothy C Tan; Victor Cohen; Jose Banchs; Joseph R Carver; Susan E Wiegers; Randolph P Martin; Michael H Picard; Robert E Gerszten; Elkan F Halpern; Jonathan Passeri; Irene Kuter; Marielle Scherrer-Crosbie
Journal:  Circ Cardiovasc Imaging       Date:  2012-06-28       Impact factor: 7.792

Review 5.  A historical perspective of anthracycline cardiotoxicity.

Authors:  Michael S Ewer; Daniel D Von Hoff; Robert S Benjamin
Journal:  Heart Fail Clin       Date:  2011-05-14       Impact factor: 3.179

6.  Effect of statin therapy on the risk for incident heart failure in patients with breast cancer receiving anthracycline chemotherapy: an observational clinical cohort study.

Authors:  Sinziana Seicean; Andreea Seicean; Juan Carlos Plana; G Thomas Budd; Thomas H Marwick
Journal:  J Am Coll Cardiol       Date:  2012-11-07       Impact factor: 24.094

Review 7.  Cardiovascular disease: cause of morbidity and mortality in adult survivors of childhood cancers.

Authors:  Ming Hui Chen; Steven D Colan; Lisa Diller
Journal:  Circ Res       Date:  2011-03-04       Impact factor: 17.367

Review 8.  Cancer therapy-induced cardiac toxicity in early breast cancer: addressing the unresolved issues.

Authors:  Michel G Khouri; Pamela S Douglas; John R Mackey; Miguel Martin; Jessica M Scott; Marielle Scherrer-Crosbie; Lee W Jones
Journal:  Circulation       Date:  2012-12-04       Impact factor: 29.690

9.  Identification of the molecular basis of doxorubicin-induced cardiotoxicity.

Authors:  Sui Zhang; Xiaobing Liu; Tasneem Bawa-Khalfe; Long-Sheng Lu; Yi Lisa Lyu; Leroy F Liu; Edward T H Yeh
Journal:  Nat Med       Date:  2012-10-28       Impact factor: 53.440

10.  Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study.

Authors:  Erin J Aiello Bowles; Robert Wellman; Heather Spencer Feigelson; Adedayo A Onitilo; Andrew N Freedman; Thomas Delate; Larry A Allen; Larissa Nekhlyudov; Katrina A B Goddard; Robert L Davis; Laurel A Habel; Marianne Ulcickas Yood; Catherine McCarty; David J Magid; Edward H Wagner
Journal:  J Natl Cancer Inst       Date:  2012-09-05       Impact factor: 13.506

View more
  63 in total

1.  Improving prediction of cardiovascular complications of cancer therapy: what does the future hold?

Authors:  Ana Barac
Journal:  Future Cardiol       Date:  2015-08-04

Review 2.  Role of cardiovascular magnetic resonance in early detection and treatment of cardiac dysfunction in oncology patients.

Authors:  Srilakshmi Vallabhaneni; Kathleen W Zhang; Jose A Alvarez-Cardona; Joshua D Mitchell; Henning Steen; Pamela K Woodard; Daniel J Lenihan
Journal:  Int J Cardiovasc Imaging       Date:  2021-05-12       Impact factor: 2.357

Review 3.  Ischemic Heart Disease: Special Considerations in Cardio-Oncology.

Authors:  Dana Elena Giza; Fernando Boccalandro; Juan Lopez-Mattei; Gloria Iliescu; Kaveh Karimzad; Peter Kim; Cezar Iliescu
Journal:  Curr Treat Options Cardiovasc Med       Date:  2017-05

4.  The Yale Fitness Intervention Trial in female cancer survivors: Cardiovascular and physiological outcomes.

Authors:  M Tish Knobf; Sangchoon Jeon; Barbara Smith; Lyndsay Harris; Siobhan Thompson; Mitchel R Stacy; Karl Insogna; Albert J Sinusas
Journal:  Heart Lung       Date:  2017-08-10       Impact factor: 2.210

Review 5.  Specialized Care for Women: the Impact of Women's Heart Centers.

Authors:  Gina P Lundberg; Laxmi S Mehta; Annabelle S Volgman
Journal:  Curr Treat Options Cardiovasc Med       Date:  2018-08-08

6.  Cardiovascular risk and communication among early stage breast cancer survivors.

Authors:  Allison H Christian; Denalee O'Malley; Ana Barac; Suzanne M Miller; Shawna V Hudson
Journal:  Patient Educ Couns       Date:  2017-02-10

Review 7.  Pediatric Cardio-Oncology: Development of Cancer Treatment-Related Cardiotoxicity and the Therapeutic Approach to Affected Patients.

Authors:  Thomas D Ryan; Rajaram Nagarajan; Justin Godown
Journal:  Curr Treat Options Oncol       Date:  2019-05-25

Review 8.  Cardio-Oncology Education and Training: JACC Council Perspectives.

Authors:  Jose A Alvarez-Cardona; Jordan Ray; Joseph Carver; Vlad Zaha; Richard Cheng; Eric Yang; Joshua D Mitchell; Keith Stockerl-Goldstein; Lavanya Kondapalli; Susan Dent; Anita Arnold; Sherry Ann Brown; Monica Leja; Ana Barac; Daniel J Lenihan; Joerg Herrmann
Journal:  J Am Coll Cardiol       Date:  2020-11-10       Impact factor: 24.094

Review 9.  The use of cardiovascular magnetic resonance as an early non-invasive biomarker for cardiotoxicity in cardio-oncology.

Authors:  Matthew K Burrage; Vanessa M Ferreira
Journal:  Cardiovasc Diagn Ther       Date:  2020-06

Review 10.  The breast cancer patient in the cardioncology unit.

Authors:  Daniela Cardinale; Vincenzo Caruso; Carlo M Cipolla
Journal:  J Thorac Dis       Date:  2018-12       Impact factor: 2.895

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.